[Efficacy and safety of Adalimumab in Crohn's disease].

Background: Adalimumab is the first subcutaneously self administered fully human anti-TNFa.

Aim: To determine efficacy and safety of Adalimumab therapy in Crohn disease.

Methods: Literature review.

Results: Adalimumab has been evaluated for its effect in inducing and maintaining remission and its steroid-sparing effect of refractory Crohn's disease. In addition, it offers a significant treatment option in patients who have lost response to or become intolerant to Infliximab. Results also suggest efficacy of Adalimumab in fistulising Crohn's disease but more studies are needed. Adalimumab was well tolerated and studies show that all anti-TNF inhibitors have similar safety profiles.